SUN PHARMA ADVANCED RESEARCH COMPANY Financial Statement Analysis
|
||
|
The Revenues of SUN PHARMA ADVANCED RESEARCH COMPANY have decreased by -5.00% YoY .
The Earnings Per Share (EPS) of SUN PHARMA ADVANCED RESEARCH COMPANY has increased by Positive YoY. |
||
SUN PHARMA ADVANCED RESEARCH COMPANY Last 5 Annual Financial Results
[BOM: 532872|NSE : SPARC]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 |
|---|---|---|---|---|
| Operating Income | ₹72 Cr | ₹76 Cr | ₹239 Cr | ₹239 Cr |
| Operating Expenses | ₹115 Cr | ₹140 Cr | ₹180 Cr | ₹180 Cr |
| Expenses | ₹395 Cr | ₹478 Cr | ₹453 Cr | ₹453 Cr |
| Operating Profit (Excl OI) | ₹-323 Cr | ₹-402 Cr | ₹-214 Cr | ₹-214 Cr |
| Other Income | ₹1.79 Cr | ₹29 Cr | ₹11 Cr | ₹11 Cr |
| Interest | ₹9.04 Cr | ₹1.70 Cr | ₹7.64 Cr | ₹7.64 Cr |
| Depreciation | ₹12 Cr | ₹13 Cr | ₹12 Cr | ₹12 Cr |
| Profit Before Tax | ₹-343 Cr | ₹-387 Cr | ₹-223 Cr | ₹-223 Cr |
| Profit After Tax | ₹-343 Cr | ₹-387 Cr | ₹-223 Cr | ₹-223 Cr |
| Consolidated Net Profit | ₹-343 Cr | ₹-387 Cr | ₹-223 Cr | ₹-223 Cr |
| Earnings Per Share (Rs) | ₹47.86 | ₹-10.55 | ₹-11.93 | ₹-6.86 |
| PAT Margin (%) | 82.65 | -477.26 | -512.56 | -93.22 |
| ROE(%) | 276.89 | 0.00 | -121.28 | -43.41 |
| ROCE(%) | 163.94 | -311.92 | -112.35 | -41.91 |
| Total Debt/Equity(x) | 0.42 | -1.19 | 0.37 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 6,415.4 Cr |
| Revenue (TTM) | : | ₹ 1,909.5 Cr |
| Net Profit(TTM) | : | ₹ 1,584.3 Cr |
| EPS (TTM) | : | ₹ 48.8 |
| P/E (TTM) | : | 4.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUN PHARMA ADVANCED RESEARCH COMPANY | -5% | -21% | 39.7% |
| SAGILITY | -3.1% | 2.6% | -8% |
| SYNGENE INTERNATIONAL | -0.3% | -4.3% | -40.3% |
| PRIME FOCUS | -5.3% | -7.3% | 75.6% |
| INTERNATIONAL GEMOLOGICAL INSTITUTE | -2.3% | -1.3% | -3.3% |
| INDEGENE | -2.4% | 8.5% | -1.1% |
| NESCO | -0.6% | -4.1% | -24.4% |
| LATENT VIEW ANALYTICS | -4.4% | -6.8% | -28.4% |
| CMS INFO SYSTEMS | -5.8% | -1.8% | -40.6% |
SUN PHARMA ADVANCED RESEARCH COMPANY Revenues
[BOM: 532872|NSE : SPARC]
| Y-o-Y | -5.00 % |
| 5 Yr CAGR | -33.02 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹72 Cr | -5.00 | |
| Mar2025 | ₹76 Cr | -68.36 | |
| Mar2024 | ₹239 Cr | 0.00 | |
| Mar2023 | ₹239 Cr | - | |
SUN PHARMA ADVANCED RESEARCH COMPANY Operating Profit
[BOM: 532872|NSE : SPARC]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹-323 Cr | Negative | |
| Mar2025 | ₹-402 Cr | Negative | |
| Mar2024 | ₹-214 Cr | Negative | |
| Mar2023 | ₹-214 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | -450.27% | Negative | |
| Mar2025 | -532.26% | Negative | |
| Mar2024 | -89.65% | Negative | |
| Mar2023 | -89.65% | - | |
SUN PHARMA ADVANCED RESEARCH COMPANY Profit After Tax
[BOM: 532872|NSE : SPARC]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹-343 Cr | Negative | |
| Mar2025 | ₹-387 Cr | Negative | |
| Mar2024 | ₹-223 Cr | Negative | |
| Mar2023 | ₹-223 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 82.65 % | Positive | |
| Mar2025 | -477.26 % | Negative | |
| Mar2024 | -512.56 % | Negative | |
| Mar2023 | -93.22 % | - | |
SUN PHARMA ADVANCED RESEARCH COMPANY Earnings Per Share (EPS)
[BOM: 532872|NSE : SPARC]
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹48 | Positive | |
| Mar2025 | ₹-11 | Negative | |
| Mar2024 | ₹-12 | Negative | |
| Mar2023 | ₹-6.86 | - | |
SUN PHARMA ADVANCED RESEARCH COMPANY Return on Capital Employed (ROCE)
[BOM: 532872|NSE : SPARC]
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 163.94% | Positive | |
| Mar2025 | -311.92% | Negative | |
| Mar2024 | -112.35% | Negative | |
| Mar2023 | -41.91% | - | |
SUN PHARMA ADVANCED RESEARCH COMPANY Share Price vs Sensex
| Current Share Price | : | ₹197.7 |
| Current MarketCap | : | ₹ 6,415.4 Cr |
| Updated EOD on | : | Aug 14,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUN PHARMA ADVANCED RESEARCH COMPANY | -5% |
-21% |
39.7% |
| SENSEX | -0.6% |
1.1% |
-3.2% |
SUN PHARMA ADVANCED RESEARCH COMPANY related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 1000 | -0.3% | 1.7% | 4.4% |
| BSE HEALTHCARE | -0.5% | 1% | 17.4% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MICROCAP 250 | 0.4% | 2.8% | 12% |
| NIFTY SMALLCAP 500 | -0.2% | 1.6% | NA |
| NIFTY TOTAL MARKET | -0.5% | 1.5% | 4.4% |
You may also like the below Video Courses
FAQ about SUN PHARMA ADVANCED RESEARCH COMPANY Financials
How the annual revenues of SUN PHARMA ADVANCED RESEARCH COMPANY have changed ?
The Revenues of SUN PHARMA ADVANCED RESEARCH COMPANY have decreased by -5.00% YoY .
How the Earnings per Share (EPS) of SUN PHARMA ADVANCED RESEARCH COMPANY have changed?
The Earnings Per Share (EPS) of SUN PHARMA ADVANCED RESEARCH COMPANY has increased by Positive YoY .
Check out Intrinsic Value of Peers of SUN PHARMA ADVANCED RESEARCH COMPANY
Compare Stock Analytics of Peers of SUN PHARMA ADVANCED RESEARCH COMPANY
SAGILITY LTD vs SYNGENE INTERNATIONAL LTD vs PRIME FOCUS LTD
INTERNATIONAL GEMOLOGICAL INSTITUTE LTD vs INDEGENE LTD vs
SAGILITY LTD vs SYNGENE INTERNATIONAL LTD vs PRIME FOCUS LTD
INTERNATIONAL GEMOLOGICAL INSTITUTE LTD vs INDEGENE LTD vs
